Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2012

01-11-2012 | Original Paper

HIV-Infected Individuals with Co-occurring Bipolar Disorder Evidence Poor Antiretroviral and Psychiatric Medication Adherence

Authors: David J. Moore, Carolina Posada, Mili Parikh, Miguel Arce, Florin Vaida, Patricia K. Riggs, Ben Gouaux, Ronald J. Ellis, Scott L. Letendre, Igor Grant, J. Hampton Atkinson, The HIV Neurobahavioral Research Program (HNRP)

Published in: AIDS and Behavior | Issue 8/2012

Login to get access

Abstract

The contribution of bipolar disorder (BD), a prevalent serious mental illness characterized by impulsivity and mood instability, to antiretroviral (ART) and psychiatric medication adherence among HIV-infected (HIV+) individuals is unknown. We examined medication adherence among 44 HIV+/BD+ persons as compared to 33 demographically- and medically-comparable HIV+/BD− persons. Classification of adherent (≥90%) or non-adherent (<90%) based on proportion of correctly taken doses over 30 days was determined using electronic medication monitoring devices. HIV+/BD+ persons were significantly less likely to be ART adherent (47.7%) as compared to HIV+/BD− (90.9%) persons. Within the HIV+/BD+ group, mean psychiatric medication adherence was significantly worse than ART medication adherence, although there was a significant correlation between ART and psychiatric adherence levels. Importantly, 30-day ART adherence was associated with plasma virologic response among HIV+/BD+ individuals. Given the high overlap of HIV and BD, and the observed medication adherence difficulties for these persons, specialized adherence improvement interventions are needed.
Appendix
Available only for authorised users
Literature
1.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386–95.PubMedCrossRef
2.
Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). JAMA. 2000;283(2):205–11.PubMedCrossRef
3.
Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA. 1998;279(12):930–7.PubMedCrossRef
4.
Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. 1999;13(15):2061–8.PubMedCrossRef
5.
Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis. 2005;191(8):1325–30.PubMedCrossRef
6.
Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS. 2010;24(5):271–7.PubMedCrossRef
7.
Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord. 2008;108(3):225–34.PubMedCrossRef
8.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.PubMedCrossRef
9.
Kilbourne AM, Justice AC, Rollman BL, et al. Clinical importance of HIV and depressive symptoms among veterans with HIV infection. J Gen Intern Med. 2002;17(7):512–20.PubMedCrossRef
10.
Sternhell PS, Corr MJ. Psychiatric morbidity and adherence to antiretroviral medication in patients with HIV/AIDS. Aust N Z J Psychiatry. 2002;36(4):528–33.PubMedCrossRef
11.
Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;5:377–81.
12.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.PubMedCrossRef
13.
Singh N, Squier C, Sivek C, Nguyen MH, Wagener M, Yu VL. Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Arch Intern Med. 1996;156(2):197–201.PubMedCrossRef
14.
Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;15(31 Suppl 3):S136–9.
15.
Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80(3):131–41.PubMedCrossRef
16.
Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543–52.PubMedCrossRef
17.
Cournos F, McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: a critical review. Clin Psychol Rev. 1997;17(3):259–69.PubMedCrossRef
18.
Walkup J, Crystal S, Sambamoorthi U. Schizophrenia and major affective disorder among Medicaid recipients with HIV/AIDS in New Jersey. Am J Public Health. 1999;89(7):1101–3.PubMedCrossRef
19.
Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry. 2003;54(3):177–80.PubMedCrossRef
20.
Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology. 2005;30(2):401–4.PubMedCrossRef
21.
Beyer JL, Taylor L, Gersing KR, Krishnan KR. Prevalence of HIV infection in a general psychiatric outpatient population. Psychosomatics. 2007;48(1):31–7.PubMedCrossRef
22.
Atkinson J, Young C, Pham T, et al., editors. Prioritizing adherence intervention based on self assessment. New Haven: Enhancing Adherence: A State of the Science Meeting on Intervention Research to Improve Anti-Retroviral Adherence; 2005.
23.
Druss BG, Wang PS, Sampson NA, et al. Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(10):1196–203.PubMedCrossRef
24.
Robins LN, Wing J, Wittchen HU, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988;45(12):1069–77.PubMedCrossRef
25.
Walkup J, Blank MB, Gonzalez JS, et al. The impact of mental health and substance abuse factors on HIV prevention and treatment. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S15–9.PubMed
26.
Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384–90.PubMedCrossRef
27.
Li J, McCombs JS, Stimmel GL. Costs of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002;71(1–3):131–9.PubMedCrossRef
28.
Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 2004;6(6):504–18.PubMedCrossRef
29.
Keller MB. Improving the course of illness and promoting continuation of treatment of bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):10–4.PubMed
30.
Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care STDS. 2003;17(4):179–86.PubMedCrossRef
31.
Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004;16(4):501–6.PubMedCrossRef
32.
Himelhoch S, Brown CH, Walkup J, et al. HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009;23(13):1735–42.PubMedCrossRef
33.
Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q. 2008;79(1):43–53.PubMedCrossRef
34.
Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. J Clin Psychiatry. 2004;65(9):1180–9.PubMedCrossRef
35.
Kemppainen JK, Levine R, Buffum M, Holzemer W, Finley P, Jensen P. Antiretroviral adherence in persons with HIV/AIDS and severe mental illness. J Nerv Ment Dis. 2004;192(6):395–404.PubMedCrossRef
36.
Young RC, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429–35.PubMedCrossRef
37.
Beck AT, Steer RA, Brown G. BDI-II manual. San Antonio: The Psychological Corp; 1996.
38.
39.
Vriesendorp R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol. 2007;63(12):1115–21.PubMedCrossRef
40.
Twagirumukiza M, Kayumba PC, Kips JG, et al. Evaluation of medication adherence methods in the treatment of malaria in Rwandan infants. Malar J. 2010;9:206.
41.
Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed
42.
Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, Safren SA. The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS. 2009;23(6):455–62.PubMedCrossRef
43.
McAllister-Williams RH. Relapse prevention in bipolar disorder: a critical review of current guidelines. J Psychopharmacol. 2006;20(2 Suppl):12–6.PubMedCrossRef
44.
Lu M, Rogers WH, Laws MB, et al. Covered Time (CT) vs. Percent Doses Taken (PDT): comparing two MEMS summary adherence measures using Viral Loads (VL) as reference. Jersey City: Third International Conference of HIV Treatment Adherence; 2008.
45.
Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29(4):824–30.PubMedCrossRef
46.
Ellis RJ, Childers ME, Zimmerman JD, Simon DWF, Deutsch R, McCutchan JA. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J Infect Dis. 2003;187(11):1818–21.PubMedCrossRef
47.
R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010.
48.
SAS Institute. JMP® 8 User Guide. Second Edition ed. Cary: SAS Institute Inc; 2009.
49.
50.
Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.PubMedCrossRef
51.
Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9(3):355–62.PubMedCrossRef
Metadata
Title
HIV-Infected Individuals with Co-occurring Bipolar Disorder Evidence Poor Antiretroviral and Psychiatric Medication Adherence
Authors
David J. Moore
Carolina Posada
Mili Parikh
Miguel Arce
Florin Vaida
Patricia K. Riggs
Ben Gouaux
Ronald J. Ellis
Scott L. Letendre
Igor Grant
J. Hampton Atkinson
The HIV Neurobahavioral Research Program (HNRP)
Publication date
01-11-2012
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2012
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-0072-2

Other articles of this Issue 8/2012

AIDS and Behavior 8/2012 Go to the issue

Substantive Review

Depression, Alcohol Use and Adherence to Antiretroviral Therapy in Sub-Saharan Africa: A Systematic Review

Original Article

Do Coping Styles Mediate the Relationship Between Substance Use and Educational Attainment and Antiretroviral Adherence?

Original Paper

Recent Trauma is Associated with Antiretroviral Failure and HIV Transmission Risk Behavior Among HIV-Positive Women and Female-Identified Transgenders

Original Paper

Predicting Depression in Mothers With and Without HIV: The Role of Social Support and Family Dynamics

Substantive Review

Psychological Trauma and PTSD in HIV-Positive Women: A Meta-Analysis

Original Paper

Sexual Behavior as a Function of Stigma and Coping with Stigma Among People with HIV/AIDS in Rural New England
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits